SHAREHOLDER ALERT: WeissLaw LLP Investigates HemaCare Corporation

NEW YORK, Dec. 18, 2019

If you own HEMA shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://weisslawllp.com/hemacare-corporation-investigation/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

WeissLaw is investigating whether HemaCare's Board acted to maximize shareholder value prior to entering into the acquisition agreement.  As James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, said in touting the value of the acquisition to CRL, HemaCare is "a premier provider of cutting-edge research tools used in the development of these advanced [cell and gene therapies].  HemaCare's expertise is well recognized, as evidenced by the fact that it has worked on all of the cell therapy drugs approved by the U.S. Food and Drug Administration to date. In addition to enhancing [CRL's] value proposition for clients, we believe that the acquisition of HemaCare will drive profitable revenue and generate value for shareholders." 

Given these facts, WeissLaw is concerned whether the proposed acquisition agreement undervalues the Company, whether the Board ran a fair process, and whether all material information related to the proposed acquisition is fully and fairly disclosed.